Prochlorperazine

Pharmanovia Acquires Global Central Nervous System (CNS) Portfolio From Sanofi

Retrieved on: 
Monday, September 18, 2023
Health, Neurology, General Health, Research, Science, Pharmaceutical, Biotechnology, Epilepsy, Central nervous system, Depression, Prochlorperazine, Benzodiazepine, Schizophrenia, Anxiety, DSM-IV codes, AND, CNS, Vomiting, Insomnia, Acquisition, Patient, Sanofi, Nausea, Knowledge, Clobazam, Vertigo, Mental health, Geography, Pharmaceutical industry

PRESS RELEASE – FOR TRADE, BUSINESS AND MEDICAL MEDIA ONLY

Key Points: 
  • PRESS RELEASE – FOR TRADE, BUSINESS AND MEDICAL MEDIA ONLY
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230918003077/en/
    Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from global healthcare company, Sanofi.
  • The brands span four therapy areas of ongoing unmet need associated with CNS disorders - psycholeptic, anxiolytic, anti-epileptic and anti-psychotic.
  • For local indications it is advised to check the local approved label.

ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP

Retrieved on: 
Monday, August 29, 2022
Biotechnology, General Health, Pharmaceutical, Health, Security (finance), RLD, Form 10-K, Regulation of tobacco by the U.S. Food and Drug Administration, Private Securities Litigation Reform Act, Nature, Food, Health, SEC, U.S. Securities and Exchange Commission, Tablet, Nasdaq, Company, News, Failure, ANI, Risk, Terminology, Marketing, Annual report, Growth, Patient, Prochlorperazine, Management, Pharmaceutical industry

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg.

Key Points: 
  • ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg.
    ANIs Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg are the generic version of the Reference Listed Drug (RLD) Compazine and were developed in technical collaboration with Biophore India Pharmaceuticals Pvt.
  • The current annual U.S. market for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg is approximately $30.0 million, according to IQVIA/IMS Health, a leading healthcare data and analytics provider.
  • We are pleased to bring Prochlorperazine, another limited competition product to the market and provide customers and patients access to high quality generics, stated Nikhil Lalwani, President and Chief Executive Officer of ANI.
  • ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need.

Türk Telekom selects Mavenir and ComPro for 4G/5G Open vRAN Pilot

Retrieved on: 
Tuesday, March 1, 2022
Security, Technology, Mobile, Wireless, Telecommunications, Networks, Internet, RAN, Vran, TIP, BSS, Total cost of ownership, CSP, Telecom Infra Project, City, Mobile, Delta Upsilon, Fastly, Telecommunication, Computer network, Internet, Elasticity, Industry, CSPS, Adoption, Telekom, Senior, TCO, Multimedia, Total cost, CUS, Rus, Ecosystem, History, Solution, UFC Fight Night: Mousasi vs. Hall 2, Software, Prochlorperazine, Network equipment, Mobile phone, Rail transport, Renewable energy, Mavenir, Ownership, Mavenir, Türk Telekom Group, ComPro, MAVENIR, TüRK TELEKOM GROUP, COMPRO

Trk Telekoms pilot is designed to contribute to the work of Open RAN and Open Transport project groups within TIP.

Key Points: 
  • Trk Telekoms pilot is designed to contribute to the work of Open RAN and Open Transport project groups within TIP.
  • The pilot will test Open vRAN in the Trk Telekom Innovation Center and in the field on pilot sites.
  • Commenting on the release, Trk Telekoms CTO Yusuf Kra We are pleased to work with Mavenir, ComPro and TIP on this Open vRAN pilot.
  • We are pleased to have the systems integrator role in ongoing Trk Telekom 4G/5G Open vRAN pilot with support of TIP.

Cosette Pharmaceuticals Launches First Injectable Product - Prochlorperazine Edisylate Injection in the U.S.

Retrieved on: 
Tuesday, February 22, 2022
Biotechnology, Pharmaceutical, Health, Mental Health, Munitions Safety Information Analysis Center, Vomiting, Schizophrenia, Avista Capital Partners, Prochlorperazine, Suppository, Medication, Nausea, Daiichi Sankyo, Acquisition, Multimedia, Joint Medical Service (Germany), Ethanedisulfonic acid, Patient, CEO, Pharmaceutical industry, Fine chemical

Cosette Pharmaceuticals, Inc., a New Jersey-based pharmaceutical company, today announced the launch of Prochlorperazine Edisylate injection, 10 mg/2ml (5mg/ml).

Key Points: 
  • Cosette Pharmaceuticals, Inc., a New Jersey-based pharmaceutical company, today announced the launch of Prochlorperazine Edisylate injection, 10 mg/2ml (5mg/ml).
  • View the full release here: https://www.businesswire.com/news/home/20220222005360/en/
    This is the first injectable product Cosette has marketed in the U.S. and further exemplifies our strategy to expand and diversify Cosettes portfolio of offerings, said Apurva Saraf, Cosettes President and CEO.
  • According to IQVIA, annual sales for Prochlorperazine Edisylate for 12 months ended December 2021 were approximately $15M.
  • Prochlorperazine Edisylate is used to control severe nausea and vomiting.

Kaleyra Rolls Out RCS Broadcast Messages in USA, UK, and India

Retrieved on: 
Tuesday, December 14, 2021
Organization, SMS, Solution, URL, API, Company, Securities Exchange Act of 1934, Securities Act of 1933, RCS, Samsung, Calendar, NYSE, Android, Google, Telephone, COVID-19, Perception, Prochlorperazine, KLR, Rich Communication Services, Coronavirus, Black Friday, RBM, Ottawa, DIY, Communication, Mobile phone, Kaleyra

The Kaleyra agent allowing RCS (Rich Communication Services) Broadcast messaging capabilities works on the RBM (Rich Business Messaging) platform by Google.

Key Points: 
  • The Kaleyra agent allowing RCS (Rich Communication Services) Broadcast messaging capabilities works on the RBM (Rich Business Messaging) platform by Google.
  • Now under Kaleyra control, the Company expects to offer RCS messages and RCS campaigns to an expanded geographic footprint, including India.
  • RCS Broadcast messages allow Kaleyra to extend its existing RCS messaging offerings.
  • Such forward-looking statements include, but are not limited to, use of RCS Broadcast Messages by Kaleyra's customers.

Heritage Pharmaceuticals Inc. Issues Voluntary Nationwide Recall of Amikacin Sulfate Injection, USP 1gm/4 mL (250mg/mL) and Prochlorperazine Edisylate Injection, USP 10mg/2mL (5mg/mL) as a result of a sterility test failure

Retrieved on: 
Saturday, May 25, 2019
Medicine, RTT, Clinical medicine, Chemical compounds, Antiemetics, 5-HT3 antagonists, Ketones, Prochlorperazine, Ondansetron, Nausea, Vomiting

To date, Heritage has not received adverse event reports related to this event.

Key Points: 
  • To date, Heritage has not received adverse event reports related to this event.
  • Amikacin Sulfate Injection was manufactured in a sealed vial with a printed label affixed to the vial.
  • Prochlorperazine Edisylate Injection is indicated to control severe nausea and vomiting and for the treatment of schizophrenia.
  • Consumers with questions regarding this recall should contact Qualanex at 1-800-505-9291 Monday Friday, 8:00 am 5:00 pm, ESTand or [email protected] .

Nexus Pharmaceuticals Receives FDA Approval for Prochlorperazine Edisylate Injection, USP

Retrieved on: 
Thursday, February 21, 2019
Health, Pharmaceutical, Research, FDA, Science, General Health, Chemical compounds, Antiemetics, Typical antipsychotics, Medical specialties, Medicine, Chloroarenes, Hepatotoxins, Piperazines, Prochlorperazine, Nausea

Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for Prochlorperazine Edisylate Injection, USP in 10mg/2mL vial.

Key Points: 
  • Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for Prochlorperazine Edisylate Injection, USP in 10mg/2mL vial.
  • Nexus Pharmaceuticals Prochlorperazine Edisylate Injection is immediately available in cartons of 10 vials, each containing 10mg of Prochlorperazine Edisylate.
  • Prochlorperazine Edisylate Injection is indicated to control severe nausea and vomiting.
  • Prochlorperazine Edisylate Injection, USP is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS ).